Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR: Raptiva in moderate-to-severe psoriasis
NCT00256139Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Mar 2003
- Primary completion
- Oct 2004
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of efalizumab in plaque psoriasis, sponsored by Merck KGaA. Started Mar 2003; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00256139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256139.